Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs

Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity ​treatments, narrowing the early lead gained by Danish rival Novo Nordisk ‌with its Wegovy pi...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。